Literature DB >> 32422372

Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report.

Moisés A Calderon1, Susan Waserman2, David I Bernstein3, Pascal Demoly4, Jo Douglass5, Remi Gagnon6, Constance H Katelaris7, Harold Kim8, Harold S Nelson9, Yoshitaka Okamoto10, Kimihiro Okubo11, J Christian Virchow12, Lawrence DuBuske13, Thomas B Casale14, G Walter Canonica15, Hendrik Nolte16.   

Abstract

Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis with or without conjunctivitis and allergic asthma. Although several AIT guidelines exist, there remain unanswered questions about AIT that are relevant to everyday practice. Our objective was to prepare an evidence-based overview addressing the practical aspects of AIT in clinical practice based on published evidence and the experience of international experts in the field. Topics covered include interpretation and translation of clinical trial data into everyday clinical practice (eg, allergen doses and treatment duration), assessment of risk and treatment of local and systemic allergic reactions, recommendations for improvement of AIT guidelines, and identification of appropriate data for seeking regulatory approval, to name a few. Many informational gaps in AIT practice need further evaluation as products and practices evolve.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Allergic rhinitis; Allergy immunotherapy; Asthma; Clinical practice; Guidelines

Mesh:

Substances:

Year:  2020        PMID: 32422372     DOI: 10.1016/j.jaip.2020.04.071

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  2 in total

1.  Grains of Wisdom: Transgenic Rice for Oral Allergen Immunotherapy in Japanese Cedar Pollen-Allergic Patients.

Authors:  Carla Irani; Angela Haczku
Journal:  Int Arch Allergy Immunol       Date:  2020-12-15       Impact factor: 2.749

Review 2.  Update about Oralair® as a treatment for grass pollen allergic rhinitis.

Authors:  L Klimek; R Brehler; R Mösges; P Demoly; J Mullol; D Y Wang; R E O'Hehir; A Didier; M Kopp; C Bos; E Karagiannis
Journal:  Hum Vaccin Immunother       Date:  2022-06-15       Impact factor: 4.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.